LUCD Lucid Diagnostics Inc.

Nasdaq luciddx.com


$ 1.22 $ -0.03 (-2.4 %)    

Thursday, 16-Oct-2025 12:50:05 EDT
QQQ $ 602.37 $ -2.88 (-0.48 %)
DIA $ 461.60 $ -1.77 (-0.38 %)
SPY $ 663.52 $ -3.37 (-0.5 %)
TLT $ 91.17 $ 0.67 (0.74 %)
GLD $ 394.11 $ 2.95 (0.75 %)
$ 1.26
$ 1.25
$ 1.22 x 2,030
$ 1.23 x 1,300
$ 1.21 - $ 1.27
$ 0.75 - $ 1.80
1,286,661
na
273.28M
$ 1.07
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-12-2025 06-30-2025 10-Q
2 05-13-2025 03-31-2025 10-Q
3 03-24-2025 12-31-2024 10-K
4 11-12-2024 09-30-2024 10-Q
5 08-12-2024 06-30-2024 10-Q
6 05-13-2024 03-31-2024 10-Q
7 03-25-2024 12-31-2023 10-K
8 11-13-2023 09-30-2023 10-Q
9 08-14-2023 06-30-2023 10-Q
10 05-15-2023 03-31-2023 10-Q
11 03-14-2023 12-31-2022 10-K
12 11-14-2022 09-30-2022 10-Q
13 08-15-2022 06-30-2022 10-Q
14 05-16-2022 03-31-2022 10-Q
15 04-06-2022 12-31-2021 10-K
16 11-23-2021 09-30-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 ascendiant-capital-maintains-buy-on-lucid-diagnostics-raises-price-target-to-8

Ascendiant Capital analyst Edward Woo maintains Lucid Diagnostics (NASDAQ:LUCD) with a Buy and raises the price target from ...

 btig-reiterates-buy-on-lucid-diagnostics-maintains-25-price-target

BTIG analyst Mark Massaro reiterates Lucid Diagnostics (NASDAQ:LUCD) with a Buy and maintains $2.5 price target.

Core News & Articles

 Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical...

Core News & Articles

NEW YORK, Sept. 9, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company"), a comm...

 btig-maintains-buy-on-lucid-diagnostics-raises-price-target-to-25

BTIG analyst Mark Massaro maintains Lucid Diagnostics (NASDAQ:LUCD) with a Buy and raises the price target from $2 to $2.5.

 needham-reiterates-buy-on-lucid-diagnostics-maintains-3-price-target

Needham analyst Mike Matson reiterates Lucid Diagnostics (NASDAQ:LUCD) with a Buy and maintains $3 price target.

 needham-reiterates-buy-on-lucid-diagnostics-maintains-3-price-target

Needham analyst Mike Matson reiterates Lucid Diagnostics (NASDAQ:LUCD) with a Buy and maintains $3 price target.

Core News & Articles

Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical ...

 ascendiant-capital-maintains-buy-on-lucid-diagnostics-raises-price-target-to-775

Ascendiant Capital analyst Edward Woo maintains Lucid Diagnostics (NASDAQ:LUCD) with a Buy and raises the price target from ...

 lucid-diagnostics-files-for-offering-of-36m-shares-of-common-stock

-SEC Filing

 lucid-diagnostics-may-offer-sell-shares-of-common-stock-of-up-to-25m

-SEC Filing

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION